{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:40:10Z","timestamp":1792647610999,"version":"4.5.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      The present study aimed to investigate pegylated-\n                      <jats:sc>l<\/jats:sc>\n                      -asparaginase monotherapy for feline large cell lymphoma as a potential alternative to palliative corticosteroids treatment in animals whose owners declined cytotoxic chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective, descriptive case series of cats treated initially with pegylated-\n                      <jats:sc>l<\/jats:sc>\n                      -asparaginase as a sole therapy for feline large cell lymphoma is reported. The treatment protocol consisted of 12 intramuscular injections of pegylated-\n                      <jats:sc>l<\/jats:sc>\n                      -asparaginase with increasing intervals. If cats were unresponsive to pegylated-\n                      <jats:sc>l<\/jats:sc>\n                      -asparaginase monotherapy, a second-line treatment was initiated. Signalment, origin of lymphoma, staging, treatment, possible adverse events and follow-up data were extracted from the medical records. Responses and survival data were analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-two cats with lymphoma of five different anatomic types were included: alimentary, abdominal extra-alimentary, peripheral nodal, nasal\/nasopharyngeal and other (mediastinal, renal [solitary] and miscellaneous combined in one group for analytical purposes). The response rate was 74.1% (95% confidence interval\u2009=\u200963.4\u201383.5) with 38.3% (95% confidence interval\u2009=\u200927.8\u201348.8) in complete remission. The median disease-free period and calculated overall survival time were 70 days (12\u20131702+) and 79 days (1\u20131715+), respectively. The response rate was significantly correlated with the origin of the lymphoma and the combined group had a significantly lower response rate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.035). Twenty-four cats were also treated with corticosteroids. There was no significant difference in outcomes between the group treated with or without corticosteroids. Adverse events were present in a small number of cats (14\/82). The majority of these adverse events were mild to moderate in 5\/14 cats; however, the adverse events were severe enough to cause discontinuation of therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>\n                      Based on the response rate and median disease-free period, treatment with pegylated-\n                      <jats:sc>l<\/jats:sc>\n                      -asparaginase is inferior when compared with historical chemotherapy protocols. However, some cats demonstrated an exceptional long disease-free period. Therefore, pegylated-\n                      <jats:sc>l<\/jats:sc>\n                      -asparaginase could be offered as an alternative to corticosteroid therapy alone. Further studies are needed to evaluate the additional benefit over palliative corticosteroid monotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x231193536","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:21:06Z","timestamp":1694776866000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pegylated-\n                    <scp>l<\/scp>\n                    -asparaginase therapy for feline large cell lymphoma: 82 cases (2017\u20132020)"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3039-0339","authenticated-orcid":false,"given":"C\u00e9line A","family":"Bik","sequence":"first","affiliation":[{"name":"Medisch centrum voor dieren Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-0238","authenticated-orcid":false,"given":"Bart R","family":"Ruijter","sequence":"additional","affiliation":[{"name":"Medisch centrum voor dieren Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Van den Bossche","sequence":"additional","affiliation":[{"name":"Medisch centrum voor dieren Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Teske","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Veterinary Faculty, University of Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn JM","family":"Niessen","sequence":"additional","affiliation":[{"name":"Veterinary Specialist Consultations, Hilversum, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Forcada","sequence":"additional","affiliation":[{"name":"Veterinary Specialist Consultations, Hilversum, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"921","article-title":"Hematopoietic tumors of cats.","volume":"17","author":"Hardy WD","year":"1981","unstructured":"Hardy WDJr. Hematopoietic tumors of cats. J Am Anim Hosp Assoc 1981; 17: 921\u2013940.","journal-title":"J Am Anim Hosp Assoc"},{"key":"e_1_3_2_3_2","first-page":"51","article-title":"Lymphoma in the cat: an approach to diagnosis and management.","volume":"1","author":"Mooney SC","year":"1986","unstructured":"Mooney SC, Hayes AA. Lymphoma in the cat: an approach to diagnosis and management. Sem Vet Med Surg (Small Anim) 1986; 1: 51\u201357.","journal-title":"Sem Vet Med Surg (Small Anim)"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/104063870001200401"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X16666119"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2005.tb02703.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12158"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2008.0057.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1989.194.05.696"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1998.213.08.1144"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1998.tb02134.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.242.8.1104"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2012.00329.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1995.207.12.1593"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1987.190.02.174"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X13516621"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2002.tb02352.x"},{"key":"e_1_3_2_18_2","first-page":"341","article-title":"Canine lymphoma: a retrospective study (2009\u20132010).","volume":"81","author":"Mortier F","year":"2012","unstructured":"Mortier F, Daminet S, Vandenabeele S, et al. Canine lymphoma: a retrospective study (2009\u20132010). Vlaams Diergeneeskd Tijdschr 2012; 81: 341\u2013351.","journal-title":"Vlaams Diergeneeskd Tijdschr"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2007.05.008"},{"key":"e_1_3_2_20_2","first-page":"16","article-title":"Buffering the pain of local anaesthetics: a systematic review.","volume":"4","author":"Yuki M","year":"2014","unstructured":"Yuki M, Takase K, Sekine S, et al. Buffering the pain of local anaesthetics: a systematic review. J Nurs Educ Prac 2014; 4: 16.","journal-title":"J Nurs Educ Prac"},{"key":"e_1_3_2_21_2","first-page":"657","article-title":"Exposure to antineoplastic drugs outside the hospital environment.","volume":"50","author":"Meijster T","year":"2006","unstructured":"Meijster T, Fransman W, Veldhof R, et al. Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg 2006; 50: 657\u2013664.","journal-title":"Ann Occup Hyg"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15077"},{"key":"e_1_3_2_23_2","first-page":"92","volume-title":"Small animal clinical oncology","author":"Chun R","unstructured":"Chun R, Garrett L, MacEwen EG. Cancer chemotherapy. In: Withrow SJ, MacEwen EG (eds) Small animal clinical oncology. Philadelphia, PA: WB Saunders; 2001: pp 92\u2013119."},{"key":"e_1_3_2_24_2","unstructured":"Connor TH MacKenzie BA De Bord DG et al. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings. DHHS publication; no. (NIOSH) 2016-161 2016. https:\/\/stacks.cdc.gov\/view\/cdc\/41372 (2016 accessed 10 July 2022)"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S245210"},{"key":"e_1_3_2_26_2","first-page":"74","article-title":"Optimizing pegylated asparaginase use: an institutional guideline for dosing, monitoring and management.","volume":"26","author":"Bade NA","year":"2020","unstructured":"Bade NA, Lu C, Patzke CL, et al. Optimizing pegylated asparaginase use: an institutional guideline for dosing, monitoring and management. J Oncol Pract 2020; 26: 74\u201392.","journal-title":"J Oncol Pract"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712590802586058"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(90)90193-W"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2022.105854"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X221101533"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5810.2004.0053b.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544040-00003"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X20984363"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2009.00813.x"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/51.2.565"},{"key":"e_1_3_2_36_2","first-page":"127","article-title":"Canine lymphoma: cytologic study and response to therapy.","volume":"43","author":"Tozon N","year":"2006","unstructured":"Tozon N, Samardzija P, Prijic S. Canine lymphoma: cytologic study and response to therapy. Slov Vet Zb 2006; 43: 127\u2013133.","journal-title":"Slov Vet Zb"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12081"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/ani12070900"},{"key":"e_1_3_2_39_2","first-page":"1","article-title":"Retrospective study of adverse events of chemotherapy in cats.","volume":"46","author":"Dos Santos Cunha SC","year":"2018","unstructured":"Dos Santos Cunha SC, Silva FB, Corgozinho KB, et al. Retrospective study of adverse events of chemotherapy in cats. Acta Sci Vet 2018; 46: 1\u201312.","journal-title":"Acta Sci Vet"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200003)34:3<200::AID-MPO7>3.0.CO;2-T"},{"key":"e_1_3_2_41_2","first-page":"176","article-title":"Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007\u20132012.","volume":"57","author":"Blake MK","year":"2016","unstructured":"Blake MK, Carr BJ, Mauldin GE. Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007\u20132012. Can Vet J 2016; 57: 176.","journal-title":"Can Vet J"},{"key":"e_1_3_2_42_2","first-page":"993","article-title":"Epizootiologic characteristics of canine and feline leukemia and lymphoma.","volume":"28","author":"Dorn CR","year":"1967","unstructured":"Dorn CR, Taylor DO, Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. Am J Vet Res 1967; 28: 993\u20131001.","journal-title":"Am J Vet Res"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/v11110993"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X231193536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X231193536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X231193536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:31:11Z","timestamp":1792647071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X231193536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/1098612X231193536"],"URL":"https:\/\/doi.org\/10.1177\/1098612x231193536","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"article-number":"1098612X231193536"}}